Abstract
Rising evidence has shown the development of resistance to vascular endothelial growth factor receptor (VEGFR) inhibitors in the practices of cancer therapy. It is reported that the efficacy of axitinib (AX), a VEGFR inhibitor, is limited in the treatment of breast cancer as a single agent or in combination with other chemotherapeutic drugs due to the probability of rising population of cancer stem-like cells (CSCs) caused by AX. The present study evaluated the effect of dopamine (DA) improving AX’s efficacy on MCF-7/ADR breast cancer in vitro and in vivo, and developed a pharmacokinetic-pharmacodynamic (PK-PD) model describing the in vivo experimental data and characterizing the interaction of effect between AX and DA. The results showed that AX up-regulated the expression of breast CSC (BCSC) markers (CD44+/CD24−/low) in vivo, and DA significantly synergized the inhibitory effect on tumor growth by deducting the BCSC frequency. The PK-PD model quantitatively confirmed the synergistic interaction with the parameter estimate of interaction factor ψ 2.43. The dose regimen was optimized as 60 mg/kg AX i.g. b.i.d. combined with 50 mg/kg DA i.p. q3d in the simulation study on the basis of the PK-PD model. The model where DA synergistically enhances the effect of AX in an all-or-none manner provides a possible solution in modeling the agents like DA. Moreover, the outcome of AX and DA combination therapy in MCF-7/ADR breast cancer provided further insight of co-administering DA in the treatment of the possible CSC-causing AX-resisting breast cancer. And this combination therapy has the prospect of clinical translation.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
Lang JE, Wecsler JS, Press MF, Tripathy D. Molecular markers for breast cancer diagnosis, prognosis and targeted therapy. J Surg Oncol. 2015;111:81–90.
Mohamed A, Krajewski K, Cakar B, Ma CX. Targeted therapy for breast cancer. Am J Pathol. 2013;183:1096–112.
Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579–91.
McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist. 2000;5:3–10.
Hu-Lowe DD et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008;14:7272–83.
Cohen EEW et al. A phase II trial of axitinib in patients with various histologic subtypes ofadvanced thyroid cancer: long-term outcomes and pharmacokinetic/ pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014;74:1261–70.
Schiller JH et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol. 2009;27:3836–41.
Spano J, Moore MJ, Pithavala YK, Ricart AD, Kim S, Rixe O. Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. Invest New Drugs. 2012;30:1531–9.
Spano J et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet. 2008;371:2101–8.
Fruehauf J et al. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res. 2011;17:7462–9.
Rixe O et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007;8:975–84.
Wilmes LJ et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging. 2007;25:319–27.
Rugo HS et al. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol. 2011;29:2459–65.
Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2002;2:101–12.
Marquette C, Nabell L. Chemotherapy-resistant metastatic breast cancer. Curr Treat Options Oncol. 2012;13:263–75.
Liu K, Ding S. Target practice: modeling tumors with stem cells. Cell. 2012;149:1185–7.
Calcagno AM et al. Prolonged drug selection of breast cancer cells and enrichmentofcancer stem cellcharacteristics. J. NatlCancerInst. 2010;102:1637–52.
Ablett MP, Singh JK, Clarke RB. Stem cells in breast tumours: are they ready for the clinic? Eur J Cancer. 2012;48:2104–16.
Conley SJ et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc. Natl Acad Sci U S A. 2012;109:2784–9.
Chinchar E et al. Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells. Vasc Cell. 2014;6:1–12.
Wang S et al. Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: involvement of eradicating cancer stem-like cells. Biochem Pharmacol. 2015;95:98–109.
Hao F et al. Pharmacokinetic-pharmacodynamic modeling of the anti-tumor effect of sunitinib combined with dopamine in the human non-small cell lung cancer xenograft. Pharm Res. 2017;34:408–18.
Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol. 2000;40:67–95.
Jiang W et al. The role ofpredictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation. Int J Pharm. 2011;418:151–60.
Li M et al. Preclinical pharmacokinetic/pharmacodynamic models to predict schedule-dependent interaction between erlotinib and gemcitabine. Pharm Res. 2013;30:1400–8.
Li J et al. Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment ofA549 human NSCLC xenograft mice. Acta Pharmacol Sin. 2016;37:930–40.
Wu Q et al. Pharmacokinetic-pharmacodynamic modeling of the anticancer effectoferlotinib in ahuman non-smallcelllung cancerxenograftmousemodel. Acta Pharmacol Sin. 2013;34:1427–36.
Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55.
Ma Y, Li J, Su Q, Chen W, Lu W, Zhou T. A liquid chromatography-tandem mass spectrometric method for the determination of axitinib in nude mouse plasma: development, validation and application to a pharmacokinetic study. J Chin Pharm Sci. 2016;25:342–50.
Pharmacology Review(s) [homepage on the Internet]. Silver Spring: U.S. Food & Drug Administration; c1906-2017 [updated 17 Feburary 2012, cited 4 December 2017]. https://www.accessdata.fda.gov/drugsattfda_docs/nda/2012/202324orig1s000pharmr.pdf
Koch G, Walz A, Lahu G, Schropp J. Modeling of tumor growth and antic-ancer effects of combination therapy. J Pharmacokinet Pharmacodyn. 2009;36:179–97.
Reyner EL et al. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions. Drug Metab Dispos. 2013;41:1575–83.
Zientek MA et al. In vitro kinetic characterization of axitinib metabolism. Drug Metab Dispos. 2016;44:102–14.
Bhatt-Mehta V, Nahata MC. Dopamine and dobutamine in pediatric therapy. Pharmacotherapy. 1989;9:303–14.
Javoy F, Glowinski J. Dynamic characteristic of the 'functional compartment' of dopamine in dopaminergic terminals of the rat striatum. J Neurochem. 1971;18:1305–11.
Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther. 1997;35:401–13.
FDA approves inlyta (axitinib) for advanced kidney cancer. Oncol Times. 2012;34:18.
Wang F, Mi Y. Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2. Mol Med. 2012;18:887–98.
Lu L, Saha D, Martuza RL, Rabkin SD, Wakimoto H. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma. J Neurooncol. 2015;121:91–100.
Zhang K, Waxman DJ. Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model. Mol Cancer Ther. 2013;12:787–98.
Chen RC, Lin NU, Golshan M, Harris JR, Bellon JR. Internal mammary nodes in breast cancer: diagnosis and implications for patient management—a systematic review. J Clin Oncol. 2008;26:4981–9.
Hayashi K et al. Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium. J Cell Biochem. 2009;106:992–8.
Wang X et al. Effects ofpsoralen as an anti-tumor agent in human breast cancer MCF-7/ADR cells. Biol Pharm Bull. 2016;39:815–22.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
Munshi, A, Hobbs, M. & Meyn, R. E. in In Vitro Assays. Chemosensitivity Vol. 1 (ed. Rosalyn D. B.) 21-29 (Humana Press: Totowa, 2005).
Liu S, Wicha MS. Targeting breast cancer stem cells. J Clin Oncol. 2010;28:4006–12.
Tsoularis A, Wallace J. Analysis of logistic growth models. Math Biosci. 2002;179:21–55.
Simeoni M et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res. 2004;64:1094–101.
Acknowledgements
This study was supported by the National Natural Science Foundation of China (Grant No. 81473277).
Author information
Authors and Affiliations
Contributions
T.Z., W.L., and Y.M. designed research; Y.M., S.W., J.L., and L.Y. performed research; Y.M., Y.R., and T.G. analyzed the data; Y.M. and T.Z. wrote the paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Ma, Yh., Wang, Sy., Ren, Yp. et al. Antitumor effect of axitinib combined with dopamine and PK-PD modeling in the treatment of human breast cancer xenograft. Acta Pharmacol Sin 40, 243–256 (2019). https://doi.org/10.1038/s41401-018-0006-x
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41401-018-0006-x
Keywords
This article is cited by
-
Implications of flavonoids as potential modulators of cancer neovascularity
Journal of Cancer Research and Clinical Oncology (2020)
-
Preclinical PK/PD model for the combinatorial use of dexamethasone and sulpiride in the treatment of breast cancer
Acta Pharmacologica Sinica (2019)